Sign in
CompletedNo phase

Late-Onset Neonatal Sepsis: A Case-Control Study

Key facts

Who runs it
Mersin University
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
128 people enrolled
Started
1 Jul 2020
Ended
1 Jul 2025
Type of study
Observational, 2 groups
Treatments tested
  • serum biomarker
Record updated
9 June 2026

Who can take part

Age
3 days to 28 days
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Term newborn
  • Late-onset neonatal sepsis

Who cannot take part

  • Congenital metabolic disease
  • Hematological diseases
  • Preterm newborn
  • Major congenital anomaly
  • Hemolytic anemia
  • Congenital leukemia
  • Dyserythropoietic anemia
  • Early-onset neonatal sepsis; Control group
  • Neonatal jaundice (indirect hyperbilirubinemia)
  • Transient neonatal tachypnea
  • Early neonatal sepsis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The diagnosis of late-onset sepsis in term neonates has been studied less than that of early-onset sepsis. Procalcitonin (PCT) and C-reactive protein (CRP) are commonly used biomarkers in the diagnosis of sepsis. However, their diagnostic advantage for late-onset sepsis (GNS) is debatable. Rapid and accurate diagnosis of late-onset infection in newborn infants remains a significant goal in clinical practice worldwide. Therefore, the accuracy of diagnostic tests needs to be improved. This study aimed to evaluate the effectiveness of serum biomarkers in the diagnosis and treatment monitoring of late neonatal sepsis (LOS) in term neonates.

The 2 groups in the trial

  • Patient group 1 control group 2

    The control group was selected to match the sepsis group as closely as possible (at a 1:1 ratio) in terms of demographic characteristics and taking gestational age into account

    Treatment: serum biomarker

  • control group and patient group

    Neonates born before the 38th week of pregnancy, with major congenital anomaly or congenital metabolic disease, babies born to substance-dependent mothers, with hemolytic anemia or other hematological diseases (such as congenital leukemia, dyserythropoetic anemia, or severe hemolytic diseases), and babies diagnosed with immunodeficiency, with early-onset sepsis, with histories of surgery, or with deficient laboratory data were excluded. All babies diagnosed with LOS and meeting none of the exclusion criteria were enrolled and constituted the LOS cohort. In case of more than one LOS episode, only the first was included in the analysis. Babies with neonatal jaundice (indirect hyperbillurubinemia) of non-hemolytic causes that resolved with phototherapy alone, with transient neonatal tachypnea resolving within the first 24 hours and with no sepsis attack, and infants with non-infectious causes admitted to the NICU were included in the control group. Exclusion criteria for the control gr

    Treatment: serum biomarker

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of Traditional Biomarkers and Novel Inflammatory Indices in the Diagnosis of Late-Onset Neonatal Sepsis: A Case-Control Study
Record updated
9 June 2026